Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its…
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its…
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its…
STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT
Article contentNEW YORK, July 27, 2024 (GLOBE NEWSWIRE) — NEW YORK, July 27, 2024 / GlobeNewswire/–Monteverde & Associates PC (the “M&A Class Action Firm”), has…
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its…
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its…
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its…
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its…